## **Core Concept**
Glycoprotein IIb/IIIa receptor antagonists are a class of antiplatelet drugs that inhibit platelet aggregation by blocking the glycoprotein IIb/IIIa receptor on the platelet surface. This receptor is crucial for platelet aggregation as it binds fibrinogen, which cross-links platelets. By inhibiting this receptor, these drugs prevent thrombus formation.

## **Why the Correct Answer is Right**
The correct answer, **.**, refers to **Abciximab**. Abciximab is a monoclonal antibody that specifically binds to the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen from binding and thereby inhibiting platelet aggregation. This mechanism is highly effective in preventing thrombotic events during procedures like percutaneous coronary intervention (PCI).

## **Why Each Wrong Option is Incorrect**
- **Option A:** While there are several antiplatelet drugs, without a specific name provided, it's hard to directly refute. However, common glycoprotein IIb/IIIa inhibitors include abciximab, eptifibatide, and tirofiban.
- **Option B:** This option is blank and thus cannot be considered a viable pharmacological agent.
- **Option C:** Similarly, this option is blank and does not represent a known glycoprotein IIb/IIIa receptor antagonist.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **glycoprotein IIb/IIIa inhibitors** like abciximab are particularly useful in the setting of **acute coronary syndromes** and during **PCI** to prevent thrombotic complications. These drugs have a rapid onset and short half-life, making them ideal for use in acute settings.

## **Correct Answer:** . **Abciximab**